What is Evogene?
Evogene operates at the vanguard of computational chemistry, utilizing sophisticated artificial intelligence to streamline the discovery and design of novel small molecules. The company's core competency lies in its ability to accelerate research and development cycles for both pharmaceutical and agricultural applications. By transforming complex biological data into actionable molecular insights, Evogene effectively bridges the gap between theoretical scientific discovery and the commercialization of viable, high-impact products. Its business model relies heavily on strategic collaborations and internal innovation, allowing it to maintain a competitive edge in a rapidly evolving technological landscape.
The firm's market position is defined by its unique AI-driven architecture, which optimizes the transition from initial research to practical application. As the demand for precision-engineered molecules grows across global industries, Evogene's platform serves as a foundational technology for partners seeking to reduce development timelines and improve success rates in molecule design.
How much funding has Evogene raised?
Evogene has raised a total of $15M across 2 funding rounds:
Stock Offering
$5M
Share Placement
$10M
Stock Issuance/Offering (2013): $5M, investors not publicly disclosed
Share Placement (2020): $10M led by Alpha Capital Anstalt and ARK Investment Management LLC
Key Investors in Evogene
Alpha Capital Anstalt
A private investment firm focused on long-term capital appreciation and strategic equity positions in technology-driven enterprises.
ARK Investment Management LLC
A prominent investment manager specializing in thematic investing and disruptive innovation across the technology and life sciences sectors.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the company's ongoing research and development initiatives.
What's next for Evogene?
With the recent influx of capital, Evogene is well-positioned to scale its internal innovation initiatives and deepen its strategic partnerships. The company is expected to focus on expanding its AI platform's capabilities, potentially targeting new therapeutic areas or agricultural sectors that require high-throughput molecular screening. As the firm moves into this next phase of growth, the focus will likely remain on enhancing the scalability of its computational models and securing long-term commercial agreements that validate its technology in real-world settings. Investors will be monitoring the company's ability to translate its computational breakthroughs into tangible, revenue-generating assets within the pharmaceutical and agricultural markets.
See full Evogene company page
